logo
China Pharma Pure Powder manufacturer
Request A Quote
English
English
Français
Deutsch
Italiano
Русский
Español
Português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
Indonesia
Tiếng Việt
ไทย
বাংলা
فارسی
Polski
Home ProductsAPI Active Pharmaceutical IngredientLiraglutide 98% Api Active Principle Ingredient Antidiabetic Function 204656-20-2
Liraglutide 98% Api Active Principle Ingredient Antidiabetic Function 204656-20-2
Liraglutide 98% Api Active Principle Ingredient Antidiabetic Function 204656-20-2 Liraglutide 98% Api Active Principle Ingredient Antidiabetic Function 204656-20-2 Liraglutide 98% Api Active Principle Ingredient Antidiabetic Function 204656-20-2 Liraglutide 98% Api Active Principle Ingredient Antidiabetic Function 204656-20-2

Liraglutide 98% Api Active Principle Ingredient Antidiabetic Function 204656-20-2

Product Details:
Place of Origin: Xi'an ,China
Brand Name: Wango
Model Number: WG-0031
Payment & Shipping Terms:
Minimum Order Quantity: 10gram every time
Price: FOB price USD48-60 /gram,price ,can be negotiable freely .
Packaging Details: 1mg,1g,10g small bottle ,1kg with double plastic container inside/Aluminum foil bag .Or as your request.
Delivery Time: 3-5 working days
Payment Terms: Western Union, L/C, T/T, MoneyGram
Supply Ability: 10kilogram 0ne month
Contact Now

Detail Information
Appearence: White Crystal Powder Other Name: Semaglutide
Packing: 1mg,1g,10g Small Bottle Function: Antidiabetic Treatments
Highlight:

Liraglutide Api Active Principle Ingredient

,

Api Active Principle Ingredient Antidiabetic

,

204656-20-2

Product Description

Liraglutide 98% purity Cas 204656-20-2 antidiabetic function chemical manufacturer with top quality !

Liraglutide 98% Api Active Principle Ingredient Antidiabetic Function 204656-20-2 0

Product Name

Liraglutide

Cas No.

204656-20-2

Sequence

H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(N-ε-(Nα-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Molecular Formula

C172H265N43O51

Molar Mass

3751.202 g/mol

Purity

≥98%

Impurity

≤0.5%

Storage Temperature

2-8ºC

Packing Size

100MG/Bottle, 1G/Bottle,10G/Bottle or at customers reqirement.

Pharmacodynamic and pharmacology properties

 

Tolerability

 

Subcutaneous liraglutide, as monotherapy or add-on therapy to antidiabetic drugs, was generally well tolerated in clinical trials and extension studies (B2 years’ treatment). Based on a pooled analysis of five double-blind trials (C26 weeks’ duration), 7.8 % of liraglutide recipients discontinued treatment because of adverse events compared with 3.4 % of patients in the comparator groups[3]. Nausea (2.8 % in liraglutide groups vs. 0 % in comparator groups) and vomiting (1.5 vs. 0.1 %) were the most common adverse reactions leading to treatment withdrawal, with most patients withdrawing within the first 2–3 months of liraglutide therapy. Most treatment-emergent adverse events occurring during liraglutide therapy were gastrointestinal (GI) in nature, of mild or moderate intensity and resolved after the first few weeks of treatment[3]. Injection site reactions (e.g. rash and erythema) occurred in approximately 2 % of patients participating in five double-blind trials (C26 weeks’ duration), with 0.2 % of patients discontinuing treatment because of these events[4].
In postmarketing surveillance studies there have been reports of acute pancreatitis, including fatal and non-fatal haemorrhagic or necrotizing pancreatitis, in patients treated with liraglutide[3, 4]. In clinical trials, 13 liraglutide recipients and one glimepiride recipient experienced pancreatitis (2.7 vs. 0.5 cases/1,000 patient-years) [3]. Of the 13 liraglutide-treated recipients, nine patients had acute pancreatitis and four had chronic pancreatitis, with some of the 13 patients having other risk factors for pancreatitis, such as a history of cholelithiasis or alcohol abuse. Although clinical causality could not be established, one of the 13-liraglutide recipients had pancreatitis with necrosis that led to death[3].
In clinical trials, seven cases of papillary thyroid carcinoma were reported in liraglutide-treated patients compared one case in a comparator group (1.5 vs. 0.5 cases/ 1,000 patient-years)[3]. Most of these papillary thyroid carcinomas were <1 cm in greatest diameter and were diagnosed in surgical pathology specimens after thyroidectomy prompted by results from protocol-specified screening procedures[3]

References

 

Approaches to treating T2DM, a disease characterized by the dual defect of islet cell dysfunction and insulin resistance, include agents that increase the secretion of insulin by the pancreas (secretagogues), agents that increase the sensitivity of target organs to insulin (sensitizers), and agents that decrease the glucose absorption rate from the gastrointestinal tract.Liraglutide, the GLP-1 receptor agonist to reach the market, possesses a 97% homology to GLP-1 with only two amino acid changes and the addition of a fatty acid side chain. Specifically, the lysine in position 34 has been replaced with an arginine, and the lysine in position 26 has been modified with a C16 acyl chain via a glutamoyl spacer. Liraglutide derives its resistance to DPP-4 degradation from its propensity to form micelles and to bind to albumin. Unlike its predecessor exenatide, which requires two daily subcutaneous injections before the first and last meals of the day, liraglutide is approved as a once-daily treatment regimen and may be used in combination with metformin or a sulfonylurea in patients with insufficient glycemic control with either monotherapy or combined dual therapy. It is also approved in combination with the dual therapy of metformin and a thiazolidinedione in patients with insufficient glycemic control. Liraglutide displayed a binding potency of 61 pM (EC50= 55 pM for GLP-1) for the cloned human GLP-1 receptor.

 

FAQ

 

Q1: Are you a manufacturer?


Yes, Wango Biopharm have concentrated on Organic synthesis over 12 years since 2008.
Advanced R&D technology, 380,000 categories chemical reagent are in stock.
Trading products we will serve for you with our ISO supplier system, making your purchasing risk into the lowest.
In addition, we provide the customization service of a new compound from lab to bulk manufacturing.

Q2: How to contact with us?


You can contact with us on Made-in-China, the Average Response Time is 0-4h on Work time, <24h on Non-work time.
For every inquiry, our sales will provide the one-for-one service for you.

Q3:Which kind of payment do you accept?


Normal orders: Company account(The price will be 5%-13% extra discount)
Sample/small orders: Paypal(The 5-10% extra fee),Western Union etc.
About the payment term, we will negotiate alone.

Q4:How to confirm the Product Quality before placing orders?


1st, you can get free samples for some products, just pay the basic cost for us.
2nd,Also you can send the specification or your quest to us, we will customize the products for you.
3rd,We emphasis that our whole company make a living with organic chemical and customers, we absolutely impossible to sale any fake goods, unqualified goods, it is shame! And None False certificate/lie/illegal thing in our sales net!

Q5:How do you treat quality complaint?


The customer complaint handling procedures is the key part in Our ISO management system. We will set up an investigation team for your complaint, and give the handling plan and our corrective and preventive measures within a limited time.

Q6:Package


We will refer the MSDS to design the package standard and show you at the PI or Quotation list.
If you want customize package and haven't go against the principle of science, we will do as your request. The cost will be calculate your request.
For dangerous goods, only one style of package, we will do as the UN standard.

Q7:Shipping


We have R&D and manufactured chemicals for 12 years, we have rich experience on Shipping, Many famous companies cooperated with us stably, we are good at shipping all kinds of chemicals.
General goods: The best service, price and lead time.
Dangerous goods: The professional cooperated company, the details please check our website.

 

 

Liraglutide 98% Api Active Principle Ingredient Antidiabetic Function 204656-20-2 1

 

 

 

Tag:

Eczema API Active Pharmaceutical Ingredient

Antihypertensive API Active Pharmaceutical Ingredient

99% API Active Pharmaceutical Ingredient

Get in touch with us

Enter Your Message

You Might Be Into These